Altamira Therapeutics, Ltd. (NASDAQ: CYTO) is engaged within the research and development of RNA-based therapies for extrahepatic targets and unmet medical needs. Shares of the therapeutics company are rallying 46% through early trading on Friday, March 3, 2023. Over the past three months, Altamira Therapeutics has seen average daily volume of 41,430 shares. However, volume of 16.73 million shares or dollar volume of around $62.57 million, has already exchanged hands through early trading.
Shares of Altamira Therapeutics are gaining after the company announced data from a recent peer-reviewed clinical study involving the company’s Bentrio nasal spray versus a saline control. The study involved comparing Bentrio’s residence time and rheological properties compared to the standard saline solution.
The data demonstrated Bentrio’s superior nasal residence time of up to 3.5 hours compared to the saline control group. Bentrio was shown to be safe and well-tolerable, while the extended nasal residence time is seen as protective to nasopharyngeal areas. This is important because Bentrio’s extended nasal residence time supports protection against allergies and other airborne particles.
Altamira Therapeutics conducted the study on eight healthy volunteers who were given either Bentrio or a traditional saline nasal spray marked with a fluorescent agent to track distribution and residence time. Volunteers given Bentrio were found to have the spray widely distributed throughout the lower and middle parts of the nasal cavity. Researchers were able to detect the Bentrio protective film for up to 240 minutes, compared to the saline group’s 60 minute nasal residence time.
“Importantly, the formulation also reached the oropharynx, remaining in place for up to 240 min compared with 60 min in the control group. This feature is particularly important, since airborne viruses and allergens come into contact with both the nasal mucosa and oropharyngeal cavity,” noted the published peer-reviewed study.
The study’s results were published in Drug Development and Industrial Pharmacy, which can be viewed here: https://www.tandfonline.com/doi/full/10.1080/03639045.2023.2183724
Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/